Suchergebnisse - "2494G1JF75"

PubPharm (587)

1

Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa

enthalten in: Clinical pharmacology and therapeutics | 2024

von Chupradit, S. | Wamalwa, D. | Maleche-Obimbo, E. | +11

2

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance

enthalten in: The Journal of antimicrobial chemotherapy | 2024

von Abdullahi, A. | Diaz, A. | Fopoussi, O. | +5

3

Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania

enthalten in: PloS one | 2024

von Jiwa, N. | Ketang'enyi, E. | Nganyanyuka, K. | +12

4

Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study) : an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

enthalten in: The lancet. HIV | 2024

von Bekker, A. | Salvadori, N. | Rabie, H. | +10

ErratumIn: Lancet HIV. 2024 Apr 5;:. - PMID 38588690

5

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV

enthalten in: The Pediatric infectious disease journal | 2023

von Chabala, C. | Turkova, A. | Kapasa, M. | +113

6

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children : A Substudy of the CHAPAS-4 Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waalewijn, H. | Szubert, A. | Wasmann, R. | +18

7

Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients

enthalten in: Pharmacotherapy | 2023

von Salerno, S. | Capparelli, E. | McIlleron, H. | +5

8

Short-term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo

enthalten in: Basic & clinical pharmacology & toxicology | 2023

von Wen, P. | Ge, X. | Wang, Y. | +17

9

Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis

enthalten in: AIDS research and human retroviruses | 2023

von Leal, L. | Guardo, A. | Bedoya, L. | +10

10

Brief Report : Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2023

von Jacobs, T. | Mumbiro, V. | Chitsamatanga, M. | +48

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[59]